Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.33 |
| ▸ | GABRE | P78334 | 1/20 | 0.33 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16475219 | 0.87 | NNMT (0.49) | NNMTCYP2A6PDGFRBPDGFRAMEN1 | |
| SCHEMBL27485620 | 0.84 | NNMT (0.52) | NNMTCYP2A6PDGFRBPDGFRAMEN1 | |
| SCHEMBL20845882 | 0.77 | NNMT (0.46) | NNMTCYP2A6MEN1PABPC1KMT2A | |
| SCHEMBL17553321 | 0.76 | NNMT (0.45) | NNMTCYP2A6PDGFRBPDGFRAMEN1 | |
| SCHEMBL20845912 | 0.76 | NNMT (0.45) | NNMTCYP2A6PDGFRBPDGFRAMEN1 | |
| SCHEMBL17493534 | 0.76 | NNMT (0.34) | NNMTPDGFRBPDGFRAMEN1PABPC1 | |
| SCHEMBL2614474 | 0.74 | NNMT (0.55) | NNMTCYP2A6PDGFRBPDGFRAMEN1 | |
| SCHEMBL26144368 | 0.74 | NNMT (0.47) | NNMTCYP2A6PDGFRBPDGFRAMEN1 | |
| SCHEMBL19621096 | 0.74 | NNMT (0.44) | NNMTCYP2A6MEN1KMT2AOXTR | |
| SCHEMBL20845927 | 0.72 | NNMT (0.41) | NNMTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013050270-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-11 | — | — | WO | disclosed |
| US-20130090333-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090333-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | RYR2, CACNA1E, RYR1 | NNMT 4541/4885CYP2A6 919/4885PDGFRB 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.